This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III
study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks,
continuing the patient's infusion interval in the main study NCT01012323 [NGAM-01]) for 3
months. The primary objective of the study was to assess the safety and tolerability of high
infusion rates of NewGam.